Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1

In the fasted state, induction of hepatic glucose output and fatty acid oxidation is essential to sustain energetic balance. Production and oxidation of glucose and fatty acids by the liver are controlled through a complex network of transcriptional regulators. Among them, the transcriptional coactivator PGC-1α plays an important role in hepatic and systemic glucose and lipid metabolism. We have previously demonstrated that sirtuin 1 (SIRT1) regulates genes involved in gluconeogenesis through interaction and deacetylation of PGC-1α. Here, we show in vivo that hepatic SIRT1 is a factor in systemic and hepatic glucose, lipid, and cholesterol homeostasis. Knockdown of SIRT1 in liver caused mild hypoglycemia, increased systemic glucose and insulin sensitivity, and decreased glucose production. SIRT1 knockdown also decreased serum cholesterol and increased hepatic free fatty acid and cholesterol content. These metabolic phenotypes caused by SIRT1 knockdown tightly correlated with decreased expression of gluconeogenic, fatty acid oxidation and cholesterol degradation as well as efflux genes. Additionally, overexpression of SIRT1 reversed many of the changes caused by SIRT1 knockdown and depended on the presence of PGC-1α. Interestingly, most of the effects of SIRT1 were only apparent in the fasted state. Our results indicate that hepatic SIRT1 is an important factor in the regulation of glucose and lipid metabolism in response to nutrient deprivation. As these pathways are dysregulated in metabolic diseases, SIRT1 may be a potential therapeutic target to control hyperglycemia and hypercholesterolemia.

[1]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[2]  M. Birnbaum,et al.  Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1α transcription coactivator , 2007, Nature.

[3]  P. Puigserver,et al.  Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1α , 2007, The EMBO journal.

[4]  C. Newgard,et al.  Obesity-related derangements in metabolic regulation. , 2006, Annual review of biochemistry.

[5]  P. Puigserver,et al.  GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. , 2006, Cell metabolism.

[6]  Janardan K Reddy,et al.  Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[7]  D. Kelly,et al.  PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. , 2006, The Journal of clinical investigation.

[8]  M. Krieger,et al.  Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL , 2006, Journal of Molecular Medicine.

[9]  D. Mangelsdorf,et al.  LXRS and FXR: the yin and yang of cholesterol and fat metabolism. , 2006, Annual review of physiology.

[10]  P. Reiss,et al.  Ritonavir Impairs Lipoprotein Lipase–Mediated Lipolysis and Decreases Uptake of Fatty Acids in Adipose Tissue , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Madeleine Lemieux,et al.  Sirt1 Regulates Insulin Secretion by Repressing UCP2 in Pancreatic β Cells , 2005, PLoS biology.

[12]  M. Montminy,et al.  The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism , 2005, Nature.

[13]  J. Heinecke,et al.  ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. , 2005, Physiological reviews.

[14]  Jiandie D. Lin,et al.  Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α , 2005, Cell.

[15]  M. Permutt,et al.  Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. , 2005, Cell metabolism.

[16]  Christoph Handschin,et al.  Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.

[17]  L. Guarente,et al.  Calorie restriction, SIRT1 and metabolism: understanding longevity , 2005, Nature Reviews Molecular Cell Biology.

[18]  Wilhelm Haas,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1 , 2005, Nature.

[19]  Chaodong Wu,et al.  Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. , 2005, Current drug targets. Immune, endocrine and metabolic disorders.

[20]  Christoph Handschin,et al.  Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP , 2005, Cell.

[21]  B. Rogina,et al.  Sir2 mediates longevity in the fly through a pathway related to calorie restriction. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Girard,et al.  Role of the liver in the control of carbohydrate and lipid homeostasis. , 2004, Diabetes & metabolism.

[23]  Namjin Chung,et al.  Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ , 2004, Nature.

[24]  Marc Montminy,et al.  PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3 , 2004, Nature Medicine.

[25]  T. Osborne,et al.  PGC-1α Activates CYP7A1 and Bile Acid Biosynthesis* , 2003, Journal of Biological Chemistry.

[26]  Loren Miraglia,et al.  TORCs: transducers of regulated CREB activity. , 2003, Molecular cell.

[27]  D. Mangelsdorf,et al.  Liver X receptor signaling pathways in cardiovascular disease. , 2003, Molecular endocrinology.

[28]  J. Yudkin,et al.  Metformin and its liver targets in the treatment of type 2 diabetes. , 2003, Current drug targets. Immune, endocrine and metabolic disorders.

[29]  Bruce M. Spiegelman,et al.  Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction , 2003, Nature.

[30]  P. Puigserver,et al.  Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1): Requirement for hepatocyte nuclear factor 4α in gluconeogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Kalhan,et al.  The Key Role of Anaplerosis and Cataplerosis for Citric Acid Cycle Function* , 2002, Journal of Biological Chemistry.

[32]  S. Kliewer,et al.  Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[33]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[34]  Marc Montminy,et al.  CREB regulates hepatic gluconeogenesis through the coactivator PGC-1 , 2001, Nature.

[35]  L. Guarente,et al.  Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans , 2001, Nature.

[36]  G. Rutter.  Diabetes: The importance of the liver , 2000, Current Biology.

[37]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[38]  C. Kahn,et al.  Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. , 2000, Molecular cell.

[39]  M. McVey,et al.  The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. , 1999, Genes & development.

[40]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.

[41]  H. Hobbs,et al.  The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. , 1990, Annual review of genetics.

[42]  D. Accili,et al.  The tangled path to glucose production , 2006, Nature Medicine.

[43]  D. Granner,et al.  Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. , 1992, Annual review of physiology.